Switch theme
Sign up to access all valuation multiples
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.
2006
1.0K+
LTM Revenue n/a
LTM EBITDA n/a
$9.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Ascendis Pharma has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Ascendis Pharma achieved revenue of $391M and an EBITDA of -$312M.
Ascendis Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Ascendis Pharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $286M | $391M | XXX | XXX | XXX |
| Gross Profit | $41.9M | $239M | XXX | XXX | XXX |
| Gross Margin | 15% | 61% | XXX | XXX | XXX |
| EBITDA | -$442M | -$312M | XXX | XXX | XXX |
| EBITDA Margin | -154% | -80% | XXX | XXX | XXX |
| Net Profit | -$626M | -$517M | XXX | XXX | XXX |
| Net Margin | -219% | -132% | XXX | XXX | XXX |
| Net Debt | $68.3M | $165M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Ascendis Pharma's stock price is EUR 134 (or $144).
Ascendis Pharma has current market cap of EUR 8.1B (or $8.7B), and EV of EUR 8.4B (or $9.0B).
See Ascendis Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $9.0B | $8.7B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Ascendis Pharma has market cap of $8.7B and EV of $9.0B.
Ascendis Pharma's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Ascendis Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Ascendis Pharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $9.0B | XXX | XXX | XXX |
| EV/Revenue | 23.0x | XXX | XXX | XXX |
| EV/EBITDA | -28.8x | XXX | XXX | XXX |
| P/E | -21.3x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -27.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAscendis Pharma's NTM/LTM revenue growth is n/a
Ascendis Pharma's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $0.6M for the same period.
Over next 12 months, Ascendis Pharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Ascendis Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Ascendis Pharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 36% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -80% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -29% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.6M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 78% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 84% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 164% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ascendis Pharma acquired XXX companies to date.
Last acquisition by Ascendis Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Ascendis Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Ascendis Pharma founded? | Ascendis Pharma was founded in 2006. |
| Where is Ascendis Pharma headquartered? | Ascendis Pharma is headquartered in Germany. |
| How many employees does Ascendis Pharma have? | As of today, Ascendis Pharma has 1.0K+ employees. |
| Who is the CEO of Ascendis Pharma? | Ascendis Pharma's CEO is Mr. Jan Moller Mikkelsen. |
| Is Ascendis Pharma publicy listed? | Yes, Ascendis Pharma is a public company listed on BER. |
| What is the stock symbol of Ascendis Pharma? | Ascendis Pharma trades under A71 ticker. |
| When did Ascendis Pharma go public? | Ascendis Pharma went public in 2015. |
| Who are competitors of Ascendis Pharma? | Similar companies to Ascendis Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Ascendis Pharma? | Ascendis Pharma's current market cap is $8.7B |
| What is the current revenue growth of Ascendis Pharma? | Ascendis Pharma revenue growth between 2023 and 2024 was 36%. |
| Is Ascendis Pharma profitable? | Yes, Ascendis Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
